淀粉样前体蛋白（APP）转基因小鼠的突触传递和学习缺陷需要APP的C末端切割。
Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP.
作者信息
Saganich Michael J, Schroeder Brock E, Galvan Veronica, Bredesen Dale E, Koo Edward H, Heinemann Stephen F
机构信息
Salk Institute for Biological Studies, La Jolla, California 92037, USA.
出版信息
J Neurosci. 2006 Dec 27;26(52):13428-36. doi: 10.1523/JNEUROSCI.4180-06.2006.
Abstract
Synaptic dysfunction has been shown to be one of the earliest correlates of disease progression in animal models of Alzheimer's disease. Amyloid-beta protein (Abeta) is thought to play an important role in disease-related synaptic dysfunction, but the mechanism by which Abeta leads to synaptic dysfunction is not understood. Here we describe evidence that cleavage of APP in the C terminus may be necessary for the deficits present in APP transgenic mice. In APP transgenic mice with a mutated cleavage site at amino acid 664, normal synaptic transmission, synaptic plasticity, and learning were maintained despite the presence of elevated levels of APP, Abeta42, and even plaque accumulation. These results indicate that cleavage of APP may play a critical role in the development of synaptic and behavioral dysfunction in APP transgenic mice.
摘要
在阿尔茨海默病动物模型中，突触功能障碍已被证明是疾病进展的最早相关因素之一。β淀粉样蛋白（Aβ）被认为在与疾病相关的突触功能障碍中起重要作用，但Aβ导致突触功能障碍的机制尚不清楚。在此，我们描述了证据表明APP在C末端的切割可能是APP转基因小鼠中存在的缺陷所必需的。在氨基酸664处具有突变切割位点的APP转基因小鼠中，尽管APP、Aβ42水平升高甚至有斑块积累，但仍维持了正常的突触传递、突触可塑性和学习能力。这些结果表明，APP的切割可能在APP转基因小鼠的突触和行为功能障碍的发展中起关键作用。
相似文献
1
Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP.
J Neurosci. 2006 Dec 27;26(52):13428-36. doi: 10.1523/JNEUROSCI.4180-06.2006.
2
The APP Intracellular Domain Is Required for Normal Synaptic Morphology, Synaptic Plasticity, and Hippocampus-Dependent Behavior.
J Neurosci. 2015 Dec 9;35(49):16018-33. doi: 10.1523/JNEUROSCI.2009-15.2015.
3
Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein.
J Neurosci. 2001 Jul 1;21(13):4691-8. doi: 10.1523/JNEUROSCI.21-13-04691.2001.
4
Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Ann Neurol. 2004 Jun;55(6):801-14. doi: 10.1002/ana.20101.
5
Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1δE9-deleted transgenic mice model of ß-amyloidosis.
Neurobiol Aging. 2010 Jul;31(7):1173-87. doi: 10.1016/j.neurobiolaging.2008.08.005. Epub 2008 Sep 13.
6
NSE-controlled carboxyl-terminus of APP gene over-expressing in transgenic mice induces altered expressions in behavior, Abeta-42, and GSK3beta binding proteins.
Cell Mol Neurobiol. 2005 Aug;25(5):833-50. doi: 10.1007/s10571-005-4937-7.
7
Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.
Neuroscience. 2015 Jul 9;298:357-66. doi: 10.1016/j.neuroscience.2015.04.038. Epub 2015 Apr 23.
8
Activation of large-conductance Ca(2+)-activated K(+) channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice.
Neurobiol Aging. 2010 Apr;31(4):591-604. doi: 10.1016/j.neurobiolaging.2008.05.012. Epub 2008 Jun 10.
9
Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.
Prog Neurobiol. 2003 May;70(1):1-32. doi: 10.1016/s0301-0082(03)00089-3.
10
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein.
J Neurosci. 2010 Jan 6;30(1):372-81. doi: 10.1523/JNEUROSCI.5341-09.2010.
引用本文的文献
1
Caspase cleavage of APP contributes to amyloid beta-protein induced synaptic injury.
bioRxiv. 2025 May 7:2025.04.30.651606. doi: 10.1101/2025.04.30.651606.
2
Anti-aging properties of the aminosterols of the dogfish shark.
NPJ Aging. 2024 Dec 19;10(1):62. doi: 10.1038/s41514-024-00188-8.
3
Navigating Alzheimer's Disease Mouse Models: Age-Related Pathology and Cognitive Deficits.
Biomolecules. 2024 Nov 5;14(11):1405. doi: 10.3390/biom14111405.
4
Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research.
Elife. 2024 Sep 27;13:e90633. doi: 10.7554/eLife.90633.
5
Impaired Hippocampal Long-Term Potentiation and Memory Deficits upon Haploinsufficiency of MDGA1 Can Be Rescued by Acute Administration of D-Cycloserine.
Int J Mol Sci. 2024 Sep 6;25(17):9674. doi: 10.3390/ijms25179674.
6
Firing Alterations of Neurons in Alzheimer's Disease: Are They Merely a Consequence of Pathogenesis or a Pivotal Component of Disease Progression?
Cells. 2024 Feb 29;13(5):434. doi: 10.3390/cells13050434.
7
Critical thinking of Alzheimer's transgenic mouse model: current research and future perspective.
Sci China Life Sci. 2023 Dec;66(12):2711-2754. doi: 10.1007/s11427-022-2357-x. Epub 2023 Jul 17.
8
iTRAQ-Based Proteomic Analysis of APP Transgenic Mouse Urine Exosomes.
Int J Mol Sci. 2022 Dec 30;24(1):672. doi: 10.3390/ijms24010672.
9
Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer's-like pathology in mouse and fly APP overexpression models.
Sci Adv. 2022 Jun 10;8(23):eabk2252. doi: 10.1126/sciadv.abk2252. Epub 2022 Jun 8.
10
Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer's Disease.
Front Aging Neurosci. 2022 Feb 17;14:805063. doi: 10.3389/fnagi.2022.805063. eCollection 2022.
本文引用的文献
1
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7130-5. doi: 10.1073/pnas.0509695103. Epub 2006 Apr 25.
2
Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624).
FASEB J. 2006 Jun;20(8):1254-6. doi: 10.1096/fj.05-5032fje. Epub 2006 Apr 24.
3
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.
J Neurosci. 2005 Oct 5;25(40):9096-101. doi: 10.1523/JNEUROSCI.1697-05.2005.
4
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.
J Neurosci. 2005 Aug 3;25(31):7278-87. doi: 10.1523/JNEUROSCI.1879-05.2005.
5
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease.
J Neurosci. 2005 Jun 29;25(26):6213-20. doi: 10.1523/JNEUROSCI.0664-05.2005.
6
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
Nat Med. 2005 May;11(5):556-61. doi: 10.1038/nm1234. Epub 2005 Apr 17.
7
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.
J Neuroinflammation. 2004 Dec 8;1(1):24. doi: 10.1186/1742-2094-1-24.
8
Deciphering the molecular basis of memory failure in Alzheimer's disease.
Neuron. 2004 Sep 30;44(1):181-93. doi: 10.1016/j.neuron.2004.09.010.
9
LTP and LTD: an embarrassment of riches.
Neuron. 2004 Sep 30;44(1):5-21. doi: 10.1016/j.neuron.2004.09.012.
10
Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes.
Ann Neurol. 2003 Dec;54(6):781-9. doi: 10.1002/ana.10761.
Zotero 插件